Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 8, 2007

Archemix and Isis Ink Aptamer Therapeutics Deal

  • Archemix and Isis Pharmaceuticals entered a broad intellectual property license agreement and research collaboration related to oligonucleotide-based therapeutics.

     

    The transaction provides Archemix with access to approximately 400 issued and pending Isis patents covering chemistries, analytical methods, and manufacturing methods. The license agreement is for exclusive use with aptamer therapeutics. Archemix will research, develop, and commercialize the drugs based on its Selex technology.

     

    Isis will receive milestones and royalties on aptamer therapeutics developed by Archemix that incorporate its chemistries or utilize its analytical or manufacturing methods. Additionally, Isis will receive a percentage of revenue generated by Archemix if this IP is sublicensed for the development of aptamer therapeutics. Isis also received a warrant to purchase an undisclosed number of shares of Archemix common stock.



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »